CAMBRIDGE, Mass., Mar 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45 th
<i>-Trial will evaluate safety and SVR rates with multiple 12-week
response-guided regimens of telaprevir/VX-222-based combination therapy,
including two-drug regimens of telaprevir and VX-222-</i>
<br />
<i>-Interim clinical data expected in the second half of 2010-</i>
<br />
<i>-Multiple clinical trial sites in the U.S. to enroll patients-</i>
<br />
CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 19, 2010 it will redeem the outstanding $32.1 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2013, in accordance with the terms of the
<i>-HCV: New Drug Application planned for telaprevir in second half of
2010; increasing investment in commercialization and launch preparedness
activities-</i>
<br />
<i>-CF: Development progress with two compounds in orphan disease of
cystic fibrosis; combination trial planned with VX-770 and VX-809 based
on Phase 2 data for VX-809-</i>
<br />
<i>-Pipeline: Proof-of-concept clinical trials planned for 2010 with
novel combination regimens for hepatitis C and cystic fibrosis and with
compounds for rheumatoid arthritis and epilepsy-</i>
<br />
<i>-Financial: Vertex enters 2010 with approximately $1.3 billion in
cash, cash equivalents and marketable securities and approximately $32
million in outstanding 2013 convertible debt; 2010 investment to support
long-term business objectives-</i>
<br />
<i>-VX-809 was well-tolerated at all dose levels when dosed once daily
for 28 days-</i>
<br />
<i>-Statistically significant changes observed in measurement of sweat
chloride suggest increased CFTR activity-</i>
<br />
<i>-Data support planned combination trial of VX-809 and VX-770 in
second half of 2010 for CF patients with the F508del mutation-</i>
<br />
<i>-HCV:</i><i>New Drug Application planned for telaprevir in second
half of 2010, robust commercialization and launch preparedness
activities ongoing-</i><br /><i>-CF:</i><i>Advancing development efforts in orphan disease of cystic
fibrosis; Phase 3 STRIVE trial with VX-770 completes planned enrollment,
VX-809 Phase 2 data expected in first quarter 2010-</i><br /><i>-Pipeline:</i><i>Proof-of-concept clinical trials planned for 2010
with novel combination regimens for hepatitis C and cystic fibrosis and
with compounds for rheumatoid arthritis and epilepsy-</i><br /><i>-Financial:</i><i>Vertex enters 2010 with approximately $1.3 billion
in cash, cash equivalents & marketable securities and approximately $32
million in outstanding convertible debt-</i><br />
CAMBRIDGE, Mass., Dec 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Officer. Ms. Wysenski has more than 30 years of experience in building commercial operations and
CAMBRIDGE, Mass., Dec 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per
CAMBRIDGE, Mass., Dec 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering under an effective shelf registration